Novel therapies for open-angle glaucoma

Scott M. Wentz, Nathaniel J. Kim, Jenny Wang, Annahita Amireskandari, Brent Siesky, Alon Harris

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.

Original languageEnglish
Article number102
JournalF1000Prime Reports
Volume6
DOIs
StatePublished - Nov 4 2014

Fingerprint

Open Angle Glaucoma
Retinal Ganglion Cells
Intraocular Pressure
Glaucoma
Optic Nerve Diseases
Therapeutics
Drug Delivery Systems
Patient Compliance
Biological Availability
Axons
Hemodynamics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wentz, S. M., Kim, N. J., Wang, J., Amireskandari, A., Siesky, B., & Harris, A. (2014). Novel therapies for open-angle glaucoma. F1000Prime Reports, 6, [102]. https://doi.org/10.12703/P6-102

Novel therapies for open-angle glaucoma. / Wentz, Scott M.; Kim, Nathaniel J.; Wang, Jenny; Amireskandari, Annahita; Siesky, Brent; Harris, Alon.

In: F1000Prime Reports, Vol. 6, 102, 04.11.2014.

Research output: Contribution to journalArticle

Wentz, Scott M. ; Kim, Nathaniel J. ; Wang, Jenny ; Amireskandari, Annahita ; Siesky, Brent ; Harris, Alon. / Novel therapies for open-angle glaucoma. In: F1000Prime Reports. 2014 ; Vol. 6.
@article{4f49913666ca435683e46b31bb8fbb4e,
title = "Novel therapies for open-angle glaucoma",
abstract = "Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.",
author = "Wentz, {Scott M.} and Kim, {Nathaniel J.} and Jenny Wang and Annahita Amireskandari and Brent Siesky and Alon Harris",
year = "2014",
month = "11",
day = "4",
doi = "10.12703/P6-102",
language = "English",
volume = "6",
journal = "F1000Prime Reports",
issn = "2051-7599",
publisher = "Faculty of 1000 Ltd",

}

TY - JOUR

T1 - Novel therapies for open-angle glaucoma

AU - Wentz, Scott M.

AU - Kim, Nathaniel J.

AU - Wang, Jenny

AU - Amireskandari, Annahita

AU - Siesky, Brent

AU - Harris, Alon

PY - 2014/11/4

Y1 - 2014/11/4

N2 - Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.

AB - Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targets must be developed. Such therapies may include new tissue targets for lowering intraocular pressure, molecules influencing ocular hemodynamics, and treatments providing neuroprotection of retinal ganglion cells. Furthermore, novel drug delivery systems are in development that may improve patient compliance, increase bioavailability, and decrease adverse side effects.

UR - http://www.scopus.com/inward/record.url?scp=84912020996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912020996&partnerID=8YFLogxK

U2 - 10.12703/P6-102

DO - 10.12703/P6-102

M3 - Article

VL - 6

JO - F1000Prime Reports

JF - F1000Prime Reports

SN - 2051-7599

M1 - 102

ER -